MX345717B - Dosificación controlada de clopidogrel con las terapias de inhibición del ácido gástrico. - Google Patents

Dosificación controlada de clopidogrel con las terapias de inhibición del ácido gástrico.

Info

Publication number
MX345717B
MX345717B MX2014003216A MX2014003216A MX345717B MX 345717 B MX345717 B MX 345717B MX 2014003216 A MX2014003216 A MX 2014003216A MX 2014003216 A MX2014003216 A MX 2014003216A MX 345717 B MX345717 B MX 345717B
Authority
MX
Mexico
Prior art keywords
clopidogrel
ppi
delivery
provides
aspirin
Prior art date
Application number
MX2014003216A
Other languages
English (en)
Other versions
MX2014003216A (es
Inventor
R Plachetka John
Original Assignee
Pozen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pozen Inc filed Critical Pozen Inc
Publication of MX2014003216A publication Critical patent/MX2014003216A/es
Publication of MX345717B publication Critical patent/MX345717B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona nuevas formulaciones de clopidogrel en combinación con los inhibidores de la bomba de protones (PPI, por sus siglas en inglés) y opcionalmente con los NSAID, para el uso como terapias antiplaquetarias mejoradas en el accidente cerebrovascular y en las indicaciones cardiovasculares. La invención proporciona el suministro del clopidogrel en pulsos u ondas, de tal manera que la dosis total sea paulatina/progresiva durante el transcurso del tiempo y, se combina ventajosamente con omeprazol de una manera que minimice las acciones en conflicto que estos dos fármacos pueden tienen entre sí. Además, la invención también proporciona el suministro de clopidogrel y de un PPI, y opcionalmente de aspirina, de una manera secuencial (organizada) que permitiría el suministro y el metabolismo del clopidogrel primero, seguido por el PPI, y después de los anteriores opcionalmente de la aspirina. Un modo particular de la invención implica la combinación de clopidogrel con omeprazol de liberación inmediata coformulado más aspirina con recubrimienta entérica.
MX2014003216A 2011-09-14 2012-09-14 Dosificación controlada de clopidogrel con las terapias de inhibición del ácido gástrico. MX345717B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161534666P 2011-09-14 2011-09-14
PCT/US2012/055574 WO2013040457A1 (en) 2011-09-14 2012-09-14 Controlled dosing of clopidogrel with gastric acid inhibition therapies

Publications (2)

Publication Number Publication Date
MX2014003216A MX2014003216A (es) 2014-11-21
MX345717B true MX345717B (es) 2017-02-13

Family

ID=47883798

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014003216A MX345717B (es) 2011-09-14 2012-09-14 Dosificación controlada de clopidogrel con las terapias de inhibición del ácido gástrico.

Country Status (9)

Country Link
US (2) US20150079169A1 (es)
EP (1) EP2755641A4 (es)
CN (1) CN103906506A (es)
BR (1) BR112014006105A2 (es)
CA (1) CA2848764A1 (es)
EA (1) EA029341B1 (es)
MX (1) MX345717B (es)
UA (1) UA115315C2 (es)
WO (1) WO2013040457A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015015062A1 (fr) * 2013-08-02 2015-02-05 Sanofi Comprime pharmaceutique comprenant de l'acide acetylsalicylique et du clopidogrel
CN106860398A (zh) * 2015-12-13 2017-06-20 北京蓝丹医药科技有限公司 一种高生物利用度的氯吡格雷药物组合物
CN107693524A (zh) * 2017-10-23 2018-02-16 罗铭炽 一种含阿司匹林和氯吡格雷的制备方法
CN107669690A (zh) * 2017-10-23 2018-02-09 罗铭炽 一种含阿司匹林和氯吡格雷的片剂
KR102789783B1 (ko) 2018-08-28 2025-04-03 에이치케이이노엔 주식회사 항혈소판제와 산 분비 억제제를 포함하는 약학 조성물
UY39094A (es) 2020-02-27 2021-07-30 Hk Inno N Corp Composición farmacéutica que comprende compuesto derivado de bencimidazol
CN113350338A (zh) * 2021-07-09 2021-09-07 中荣凯特（北京）生物科技有限公司 用于抗血小板凝集同时合并其它疾病治疗的药物组合物及其应用
CN114159573B (zh) * 2022-01-27 2023-01-24 中以海德人工智能药物研发股份有限公司 一种用于治疗病毒性肝炎的药物组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US7029701B2 (en) * 2000-09-11 2006-04-18 Andrx Pharmaceuticals, Llc Composition for the treatment and prevention of ischemic events
PT1411900E (pt) 2001-06-01 2010-10-11 Pozen Inc Composições farmacêuticas para a entrega coordenada de aines
US8206741B2 (en) * 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
CN101460154B (zh) * 2006-04-04 2015-07-01 Kg艾克维泽生公司 包含抗血小板剂和抑酸剂的口服剂型
US9532945B2 (en) * 2006-04-04 2017-01-03 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
JP2009532462A (ja) * 2006-04-05 2009-09-10 カディラ・ヘルスケア・リミテッド 調節放出クロピドグレル製剤
NZ600235A (en) * 2008-01-25 2013-11-29 Theranostics Lab Methods and compositions for the assessment of drug response

Also Published As

Publication number Publication date
BR112014006105A2 (pt) 2017-04-11
US20150079169A1 (en) 2015-03-19
MX2014003216A (es) 2014-11-21
US20190030008A1 (en) 2019-01-31
CN103906506A (zh) 2014-07-02
EP2755641A1 (en) 2014-07-23
WO2013040457A1 (en) 2013-03-21
CA2848764A1 (en) 2013-03-21
EA201490625A1 (ru) 2014-08-29
EP2755641A4 (en) 2015-03-18
EA029341B1 (ru) 2018-03-30
UA115315C2 (uk) 2017-10-25

Similar Documents

Publication Publication Date Title
MX345717B (es) Dosificación controlada de clopidogrel con las terapias de inhibición del ácido gástrico.
PH12020500336A1 (en) FORMULATION FOR ANTI-a4á7 ANTIBODY
PL2629754T3 (pl) Kompozycja farmaceutyczna w postaci ciekłej do podawania składników czynnych
MX2014004766A (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
MX2014004960A (es) Composiciones liposomales combinadas para terapia contra el cancer.
PH12012501364A1 (en) Antibody formulation and therapeutic regimens
MX2014005721A (es) 2-tiopirimidinonas.
MX2013006492A (es) Nueva forma de administracion de inhibidor de encefalinasa.
NZ628079A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
WO2013056054A3 (en) Peptide inhibitors of bace1
WO2012074830A3 (en) Modified release tranexamic acid formulation
MX2018008732A (es) Inhibicion de la reaccion alergica usando un inhibidor de il-33.
AU2012311443A8 (en) Prolonged inhibition of interleukin-6 mediated signaling
MX369549B (es) Un proceso para la fabricación de núcleos de tabletas duros con recubrimiento.
PL2641594T3 (pl) Powlekane powłoczką dojelitową stałe kompozycje farmaceutyczne dla inhibitorów pompy protonowej
TR201100150A2 (tr) Suda çözünür dozaj formları
MX2013002503A (es) Combinacion de inhibidores de hdac con farmacos para trombocitopenia.
MX2014006201A (es) Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse.
PL2704698T3 (pl) Postać leku do kontrolowanego uwalniania substancji czynnych
EP2760435A4 (en) AUTHENTICATIVE COATINGS FOR PHARMACEUTICAL TABLETS AND MATERIALS
PH12012502198A1 (en) Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof
MX2014003214A (es) Dosificacion paulatina de clopidogrel.
TN2013000442A1 (en) FORMULATION FOR ANTI-α4β7 ANTIBODY
NZ628867A (en) Pharmaceutical formulation containing flupirtine
GB201914040D0 (en) Dosage regimes for the administration of lag-3/pd-l1 bispecific antibody

Legal Events

Date Code Title Description
FG Grant or registration